Avidity Biosciences has been granted a patent for polynucleic acid molecules, pharmaceutical compositions, and methods to treat muscle atrophy or myotonic dystrophy. The patent involves administering an siRNA molecule conjugate to target specific sequences in muscle cells for treatment. GlobalData’s report on Avidity Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Avidity Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Avidity Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Avidity Biosciences's grant share as of January 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of muscle atrophy or myotonic dystrophy using sirna

Source: United States Patent and Trademark Office (USPTO). Credit: Avidity Biosciences Inc

A recently granted patent (Publication Number: US11872287B2) discloses a method for treating muscle atrophy or myotonic dystrophy in a subject by administering an siRNA molecule conjugate. The conjugate consists of an anti-transferrin receptor binding moiety attached to an siRNA molecule that targets a specific sequence in the human DMPK mRNA, leading to RNA interference primarily in muscle cells. This treatment approach aims to address muscle atrophy or myotonic dystrophy by targeting the DMPK mRNA sequence, excluding CUG repeats, in exons 1-13 of the human DMPK mRNA.

The method outlined in the patent involves the use of modified nucleotides, internucleotide linkages, and abasic moieties in the siRNA molecule, along with a specific length range for the molecule. Additionally, the conjugate includes a linker connecting the anti-transferrin receptor binding moiety to the siRNA molecule. The patent also specifies the formulation for parenteral administration of the siRNA molecule conjugate and the use of an anti-transferrin receptor antibody or its antigen binding fragment as the binding moiety. This innovative method offers a targeted approach to treating muscle atrophy or myotonic dystrophy, particularly associated with myotonic dystrophy type 1 (DM1), by leveraging RNA interference mechanisms in muscle cells.

To know more about GlobalData’s detailed insights on Avidity Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies